JAGX - Jaguar Health, Inc.
| Previous Close | 0.5500 |
| Open | 0.5670 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1300 |
| Day's Range | 0.5001 - 0.5670 |
| 52 Week Range | 0.3510 - 24.5000 |
| Volume | 165,555 |
| Avg. Volume | 569,438 |
| Market Cap | 9.304M |
| Beta (5Y Monthly) | 0.98 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -22.3680 |
| Earnings Date | Aug 13, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- ACCESSWIRE
Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Alleen King-Carter March 13, 2020 at 3 p.m. Eastern
The discussion is part of Napo's monthly "HIV Community Conversations" series and can be viewed on Napo's Facebook page: facebook.com/napopharma. The upcoming discussion is the seventh event in the HIV Community Conversations series, which brings key advocates and activists in the HIV community together to talk about issues that matter most to people living with and affected by HIV/AIDS.
- Simply Wall St.
The Jaguar Health (NASDAQ:JAGX) Share Price Is Down 95% So Some Shareholders Are Very Salty
Even the best investor on earth makes unsuccessful investments. But it should be a priority to avoid stomach churning...
- ACCESSWIRE
Jaguar Health Secures Non-dilutive Capital Through Sale of Royalty Rights Related to Future Mytesi Revenue Stream
Under the Agreement, Jaguar will immediately receive $0.350 million in connection with the sale of a royalty interest to Iliad entitling Iliad to receive $0.500 million of future royalties on sales of Mytesi® (crofelemer) and certain up-front license fees and milestone payments from licensees and/or distributors. Royalty payments will initiate in six months and will involve minimum monthly payments.
- ACCESSWIRE
Jaguar Health Subsidiary Napo Pharmaceuticals Wins 2019 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award
SAN FRANCISCO, CA / ACCESSWIRE / February 20, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the nonprofit American Botanical Council (ABC) ...
- ACCESSWIRE
Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Davina Otalor February 7, 2020 at 3 p.m. Eastern
SAN FRANCISCO, CA / ACCESSWIRE / February 6, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals, ...
- ACCESSWIRE
Jaguar Health Announces that Published Study Indicates Crofelemer Could be a Treatment Option for Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome
This multicenter, phase 2, randomized, double-blind, placebo-controlled trial evaluated the effect of crofelemer on abdominal pain in women with IBS-D. A total of 240 women were enrolled, and participants were randomized to crofelemer (125 mg) or placebo twice daily for 12 weeks. Following an analysis by the U.S. Food and Drug Administration-issued revised recommendations for outcome measures in IBS clinical trials in 2010, the proportion of monthly abdominal pain responders was significantly higher in the crofelemer group during months 1 through 2 (58.3% vs 45.0%, P = 0.030) as well as during the entire 3 months (54.2% vs 42.5%, P = 0.037) when compared with placebo.
- Simply Wall St.
One Thing To Remember About The Jaguar Health, Inc. (NASDAQ:JAGX) Share Price
Anyone researching Jaguar Health, Inc. (NASDAQ:JAGX) might want to consider the historical volatility of the share...
- ACCESSWIRE
Jaguar Health Announces Study to Evaluate the Safety and Effectiveness of Crofelemer for Treatment of Chronic Idiopathic Diarrhea in Non-HIV Patients
SAN FRANCISCO, CA / ACCESSWIRE / December 16, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that a clinical research study initiated and sponsored ...
- ACCESSWIRE
Jaguar Health Subsidiary Napo Pharmaceuticals to Host HIV Activism Digital Summit December 13, 2019 at 3 p.m. Eastern
The summit will feature commentary by prominent HIV advocates Bruce Richman, Maria Mejia, and Ken Williams (AKA Ken Like Barbie), as well as by Jaguar CEO Lisa Conte and Napo employee Brian Coppedge. Josh Robbins will serve as the host of the event, which will be the first completely digital, activist-led virtual program in the HIV community and is intended to continue fostering the important conversations needed to address living with HIV and living with comorbidities like HIV-associated diarrhea.
- ACCESSWIRE
Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with Transgender Advocate Yonce Jones November 22, 2019 at 3 p.m. Eastern
SAN FRANCISCO, CA / ACCESSWIRE / November 21, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo ...
- ACCESSWIRE
Article About Jaguar Health Published in Fall 2019 Issue of MicroCap Review Magazine
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. For more information about Jaguar, please visit jaguar.health. Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).
- ACCESSWIRE
MicroCap Review Magazine Fall 2019 Issue Now Available
The Digital Issue of the Fall 2019 MicroCap Review Magazine, The Official Magazine for the MicroCap Stock Market, can be read on www.StockNewsNow.com LOS ANGELES, CA / ACCESSWIRE / November 20, 2019 / ...
- ACCESSWIRE
Jaguar Health, Inc. Reports 2019 Third Quarter Financial Results
Reminder: Company to Host Investor Call Today at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business ...
- ACCESSWIRE
Jaguar Health Announces that Interim Analysis Requirement Met in Phase 2 HALT-D Study Evaluating Mytesi (Crofelemer) for Prevention and Prophylaxis of Diarrhea in Breast Cancer Patients
SAN FRANCISCO, CA / ACCESSWIRE / November 14, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that Georgetown University's Data Safety Monitoring ...
- ACCESSWIRE
Jaguar Health Appoints Ian Wendt Vice President, Commercial Strategy
SAN FRANCISCO, CA / ACCESSWIRE / November 13, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company") announced today that it has named Ian Wendt, an executive who has held commercial leadership roles across sales, marketing and operations at some of the largest brands in the pharmaceutical industry during his 25 years in the sector, to the role of vice president, commercial strategy for both Jaguar and the Company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc. "We're very happy to have appointed Ian to this key role," Lisa Conte, Jaguar's president and CEO, stated. "We believe his broad commercial leadership expertise in the pharmaceutical industry, and in the HIV sector, will play a significant role as we continue to focus on enhancing patient and market access to Mytesi® (crofelemer) for its current FDA-approved indication.
- ACCESSWIRE
Jaguar Health to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business Updates
Company Plans to File Q3 2019 10-Q on November 14, 2019 SAN FRANCISCO, CA / ACCESSWIRE / November 12, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced ...
- Benzinga
14 Low Float Stocks With High Short Interest
Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme. A stock’s float is the number ...
- ACCESSWIRE
Jaguar Health Subsidiary Napo Pharmaceuticals Enters ex-U.S. Distribution Agreement for Mytesi (Crofelemer) with TannerGAP, Inc.
SAN FRANCISCO, CA / ACCESSWIRE / October 30, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), has entered into a two-year distribution agreement ("the Agreement") with TannerGAP, Inc. ("Tanner"), a division of Tanner Pharma Group, a global provider of integrated specialty access solutions. "Our ongoing commitment is to enhance Mytesi (crofelemer) access for people living with HIV - across all populations, all countries, and we believe this agreement will help accelerate that access to Mytesi on a named patient access basis in underserved international markets," Lisa Conte, Jaguar's president and CEO commented.
- ACCESSWIRE
Jaguar Health Announces Completion of Preclinical Studies of Lechlemer, the Company's Human Drug Product Candidate for Cholera and Acute Infectious Diarrhea
SAN FRANCISCO, CA / ACCESSWIRE / October 23, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company") announced today the completion of the two short-term preclinical toxicology studies in rats and dogs intended to support continued development of lechlemer, the human drug product candidate of Jaguar's wholly-owned subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), for the symptomatic relief of diarrhea from cholera and potentially other acute infectious diarrheal conditions. The completion of these initial studies support the initiation of longer term toxicity and safety pharmacology studies that the Company expects will support the Investigational New Drug (IND) application Jaguar plans to file for lechlemer.
- ACCESSWIRE
Jaguar Health's Study Shows Mytesi (Crofelemer) May Support Treatment of Diarrhea in Cancer Patients Receiving Targeted Therapy While Also Enabling Maintenance and Tolerability of a Higher Dose of the Selected TKI
SAN FRANCISCO, CA / ACCESSWIRE / October 22, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company") announced additional findings today from the recently completed preclinical study evaluating the effects of Mytesi® (crofelemer) on diarrhea induced by a specific tyrosine kinase inhibitor (TKI). The study in healthy dogs was designed to reinforce a scientific rationale for the use of crofelemer when human patients undergo treatment with targeted cancer therapies including, but not limited to, TKIs with or without cycle chemotherapy. Specifically, the preclinical study showed that crofelemer treatment resulted in lesser incidence and severity of diarrhea with the maintenance and tolerability of a higher dose of the selected TKI.
- American City Business Journals
These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year
While initial public offerings get most of the splash, public companies also are raking in cash with follow-on offerings. How long will the Wall Street spigot stay open?
- ACCESSWIRE
MicroCap Rodeo Investor Conference - Lineup for October 15 and 16, 2019
AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16 th , 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, ...
- Benzinga
The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra ...
- ACCESSWIRE
Jaguar Health Engages Firm to Explore Potential License Agreements and Collaborations for Mytesi in China
SAN FRANCISCO, CA / ACCESSWIRE / October 10, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), today announced that the Company has engaged Angel Pond Capital LLC ("Angel Pond") to explore potential licensing agreements and collaborations for Mytesi® in China. Angel Pond was founded by Ted Wang, a former Goldman Sachs partner, with a mission to help bring quality U.S. medical care to the growing needs of patients in China.
- ACCESSWIRE
Jaguar Health Eliminates Certain Royalty Obligations Reducing Future COGS for Mytesi and Crofelemer
SAN FRANCISCO, CA / ACCESSWIRE / October 4, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), today announced that a License Termination and Settlement agreement ("LTSA") related to SP-303, a component of Mytesi® (crofelemer), has been entered between Michael Tempesta, Ph.D. ("Tempesta"), Jaguar, and Jaguar's wholly-owned subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), as well as their predecessors (collectively, "Jaguar"), regarding the license agreement Napo and Tempesta entered in 2002 (the "2002 License"). SP-303 is extracted and purified from the bark latex of the medicinal Croton lechleri tree in the Amazon rainforest.
